Innovent Biologics Inc
HKEX:1801

Watchlist Manager
Innovent Biologics Inc Logo
Innovent Biologics Inc
HKEX:1801
Watchlist
Price: 35.05 HKD -0.43% Market Closed
Market Cap: 57.4B HKD
Have any thoughts about
Innovent Biologics Inc?
Write Note

Innovent Biologics Inc
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Innovent Biologics Inc
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Innovent Biologics Inc
HKEX:1801
Short-Term Investments
ÂĄ6.7B
CAGR 3-Years
3%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Short-Term Investments
ÂĄ7.5B
CAGR 3-Years
-32%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Short-Term Investments
ÂĄ195.9m
CAGR 3-Years
21%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Short-Term Investments
ÂĄ2.5B
CAGR 3-Years
188%
CAGR 5-Years
506%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Short-Term Investments
ÂĄ1.5B
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Innovent Biologics Inc
Glance View

Market Cap
57.1B HKD
Industry
Biotechnology

In the bustling landscape of the biotechnology industry, Innovent Biologics Inc. stands out as a dynamic player committed to advancing precision medicine. Founded in 2011, this Chinese-based company has carved out a significant niche in the development of monoclonal antibodies for oncology, metabolic disorders, and autoimmune diseases. Innovent sought to bridge the gap between innovation and affordability, an ambitious vision fueled by strategic collaborations with global pharma giants and local research centers. The company’s flagship product, Tyvyt (sintilimab), is a testament to their pioneering spirit—a PD-1 inhibitor developed in partnership with Eli Lilly, which gained approval for the treatment of various cancers in China. Innovent leverages its robust in-house R&D capabilities and partnerships to craft an extensive pipeline of potential therapies, positioning itself as a linchpin in the race to address unmet medical needs across its target markets. Innovent Biologics generates revenue through strategic licensing agreements, collaborative development programs, and direct sales of its commercialized therapies. It adopts a multinational partnership model that allows it to both share development costs and tap into broader distribution channels, thus accelerating growth while minimizing financial risk. By focusing on biopharmaceuticals that address prevalent health concerns, Innovent capitalizes on the rising demand for innovative healthcare solutions in China and beyond. Furthermore, the company's vertically integrated infrastructure—from research to commercialization—ensures optimized costs and sustained profitability in a competitive industry landscape. Innovent’s financial trajectory is buoyed by its ability to balance cutting-edge scientific innovation with strategic market positioning, underscoring its reputation as a formidable force in global biotech.

Intrinsic Value
47.62 HKD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Innovent Biologics Inc's Short-Term Investments?
Short-Term Investments
6.7B CNY

Based on the financial report for Jun 30, 2024, Innovent Biologics Inc's Short-Term Investments amounts to 6.7B CNY.

What is Innovent Biologics Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 5Y
20%

Over the last year, the Short-Term Investments growth was 6%. The average annual Short-Term Investments growth rates for Innovent Biologics Inc have been 3% over the past three years , 20% over the past five years .

Back to Top